| Trial registration number
|
NCT05465798 |
Full text link
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT05465798
|
First author
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
Michael Araya
|
Contact
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
michaelarayach@gmail.com
|
Registration date
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
2022-07-20
|
Recruitment status
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
Not recruiting
|
Study design
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
RCT
|
Allocation
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
Randomized
|
Design
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
Parallel
|
Masking
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
Blind label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
Treatment
|
Inclusion criteria
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
adult participants with an infection caused by sars-cov-2 confirmed with a reverse-transcription polymerase chain reaction (rt-pcr) obtained from a nasopharyngeal swab.
|
Exclusion criteria
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
life expectancy < 6 months
currently receiving invasive mechanical ventilation at baseline.
cognitive impairment that precludes the use of wurss or understanding the informed consent form.
refusal to participate.
|
Number of arms
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
2
|
Funding
Last imported at : Dec. 15, 2022, noon
Source : ClinicalTrials.gov
|
Wohlstand Pharmaceutical
|
Inclusion age min
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
100
|
Countries
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
Chile
|
Type of patients
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
Moderate/severe disease at enrollment
|
Severity scale
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
4: Moderate/severe disease at enrollment
|
Total sample size
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
60
|
primary outcome
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
Clinical recovery;Symptom duration;Symptom severity;Symptom severity;Symptom severity;Symptom severity;Symptom severity
|
Notes
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
Phase 2
|
Arms
Last imported at : July 21, 2022, 12:30 p.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "nan", "treatment_id": 2568, "treatment_name": "Beta-glucans", "treatment_type": "Nutrition", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
|